StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy
June 22, 2015 7:03 AM EDTCantor Fitzgerald reiterates a Buy rating and $2.00 price target on StemCells (NASDAQ: STEM) ahead of GA data that is anticipated to be Presented this week. Analyst Caroline Corner expects positive results, based on interim data.
Corner commented, "We anticipate that data will be... More
StemCells (STEM) Receives Approval from Health Canada to Expand Pathway Study
June 18, 2015 8:06 AM EDTStemCells (NASDAQ: STEM) announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human... More
